This provides a potential antileukemic therapeutic strategy for T-ALL patients with Notch1 mutations, reducing the gastrointestinal side effects typically associated with pan-Notch inhibition [58]. The gene discussed is NOTCH1; the disease is acute lymphoblastic leukemia.